Applied Spectral Imaging

Applied Spectral Imaging (ASI) is a United States biomedical technology company that develops microscopy imaging systems and digital analysis software for hospitals, clinical laboratories, pathology departments, and life-science research centers. Founded in 1993, the company initially concentrated on spectral-imaging instruments for research applications before expanding into clinical cytogenetics and pathology workflows. ASI's technology combines bright-field, fluorescence, and spectral imaging with automated scanning, computer-assisted interpretation, case management, and digital archiving. Its systems are designed to help laboratories capture microscope slides, review images on screen, identify and classify cellular or chromosomal features, apply quantitative scoring, and generate or store diagnostic documentation. The company has emphasized automation as a way to improve throughput, standardize repetitive tasks, and reduce the amount of manual work required from laboratory technologists. The company's clinical scope includes chromosome analysis and karyotyping, fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), fluorescent and spectral karyotyping, metaphase and interphase detection, and pathology applications involving hematoxylin and eosin (H&E), immunohistochemistry (IHC), and tissue matching. Its platforms have been positioned for applications involving chromosomal disorders, genome instability, and oncology-related testing. Reported functionality also includes whole-slide imaging, region-of-interest annotation, quantitative IHC scoring, network connectivity, laboratory information-system integration, secure report archiving, and collaborative review. Major named product families include CytoLabView, GenASIs, HiBand, HiFISH, CytoPower, Rainbow, PathFusion, and HiPath Pro. These products cover different parts of the cytogenetics and pathology workflow, from digital chromosome analysis and FISH review to bright-field whole-slide imaging and computational tissue analysis. The company has also reported a portfolio of regulatory clearances for selected products and applications, including BandView, FISHView, SpotScan applications, and the HiPath system. ASI operates in a specialized market at the intersection of laboratory diagnostics, digital pathology, microscopy, image analysis, and biomedical software. Publicly available information identifies the company as multinational and describes use by hospitals, service laboratories, and research organizations, but does not provide sufficiently detailed and current information about ownership, revenue, employee count, geographic sales breakdown, or management succession. Those aspects are therefore not inferred here.

Applied Spectral Imaging was established in 1993 with an initial emphasis on spectral-imaging devices for the research community. Its early work focused on using optical and computational methods to collect and interpret information beyond conventional microscopy channels. In 2002, the company broadened its commercial direction by entering clinical cytogenetics and introducing CytoLabView for karyotyping and FISH imaging. This marked a shift from primarily research-oriented instrumentation toward laboratory systems intended for routine clinical workflows. The platform supported the capture and review of chromosome and fluorescence data through a computer-assisted environment. ASI expanded its automation capabilities in 2005 with an automated scanning system. The system was intended to increase case-processing throughput as laboratories handled larger sample volumes and faced shortages of skilled technical personnel. Automated scanning and image-analysis functions allowed staff to spend less time on repetitive image acquisition and more time on interpretation and reporting. The company introduced the GenASIs software platform in 2011. GenASIs was designed to digitize and automate portions of the diagnostic process, allowing physicians, medical scientists, and laboratory technologists to visualize slides and analyze cells or chromosomes using software-based algorithms. The same year, ASI introduced a high-throughput tray loader to automate sample handling and scanning. ASI subsequently expanded into digital pathology. In 2017, it introduced PathFusion and HiPath Pro as components of a pathology imaging portfolio. These products addressed bright-field pathology, whole-slide imaging, H&E and IHC visualization, quantitative analysis, and the relationship between tissue pathology and FISH results. PathFusion was positioned as a bridge between bright-field pathology and tissue-based FISH by combining whole-slide imaging, computational tissue FISH, and digital tissue matching. The company has also described a portfolio of regulatory clearances for products and applications used in clinical laboratory settings. Reported milestones include FDA clearance of BandView in 2001, FISHView in 2005, SpotScan applications for CEP XY in 2007, HER2/neu in 2010, UroVysion in 2011, and ALK in 2013, followed by clearance of the HiPath system for the HER2, ER, PR, and Ki-67 IHC family in 2015. ASI's technology and patent activity have covered spectral-imaging instrumentation, interferometry-related systems, and methods for life-science image analysis. Its broader laboratory functionality includes automated slide scanning, whole-slide image viewing, annotation and measurement, scoring, case databases, report archiving, collaborative review, network connectivity, and laboratory information-system integration. Current public information supports describing ASI as an active biomedical imaging brand, but does not establish a complete ownership history, detailed executive roster, financial profile, or comprehensive chronology of international expansion.

1. 2017PathFusion and HiPath Pro introduced

   ASI introduced PathFusion and HiPath Pro as pathology imaging products supporting bright-field imaging, whole-slide workflows, IHC, and tissue-related FISH analysis.

   Source
2. 2015HiPath FDA clearance

   The HiPath system was reported as receiving FDA clearance for an IHC application family covering HER2, ER, PR, and Ki-67.

   Source
3. 2013SpotScan ALK clearance

   A SpotScan application for ALK was reported as receiving FDA clearance.

   Source
4. 2011GenASIs and high-throughput automation

   ASI introduced the GenASIs software platform and a high-throughput tray loader to support automated image analysis and sample scanning.

   Source
5. 2011SpotScan UroVysion clearance

   A SpotScan application for UroVysion was reported as receiving FDA clearance.

   Source
6. 2010SpotScan HER2/neu clearance

   A SpotScan application for HER2/neu was reported as receiving FDA clearance.

   Source
7. 2007SpotScan CEP XY clearance

   A SpotScan application for CEP XY was reported as receiving FDA clearance.

   Source
8. 2005Automated scanning and FISHView clearance

   The company launched an automated scanning system to improve laboratory throughput and received a reported FDA clearance for FISHView.

   Source
9. 2002Entry into clinical cytogenetics

   ASI introduced CytoLabView for karyotyping and FISH imaging, broadening its focus from research instrumentation to clinical cytogenetics.

   Source
10. 2001BandView FDA clearance

    BandView received a reported FDA clearance as part of ASI's expansion into regulated clinical laboratory products.

    Source
11. 1993Company founded

    Applied Spectral Imaging was founded and began developing spectral-imaging devices for research applications.

    Source

A specialized provider of automated microscopy imaging, cytogenetics analysis, digital pathology, and spectral-imaging workflows for diagnostic and research laboratories.

• CytoLabViewClinical cytogenetics2002

  A clinical cytogenetics platform introduced for karyotyping and FISH imaging. It supports digital capture and computer-assisted review of chromosome and fluorescence data in laboratory workflows.

• GenASIsDiagnostic image-analysis software2011

  A software platform for automating parts of microscopy-based diagnostic analysis. It supports visualization, cell and chromosome assessment, classification, and algorithm-assisted identification of abnormalities.

• ASI HiPath ProDigital pathology2017

  A bright-field pathology imaging and analysis system for H&E and IHC specimens. Its described capabilities include whole-slide imaging and quantitative IHC assessment for pathology workflows.

• ASI PathFusionDigital pathology and tissue FISH2017

  A platform intended to connect bright-field pathology with FISH analysis. It combines whole-slide imaging, computational tissue FISH, and digital matching of FISH findings with H&E or IHC samples.

• ASI HiBandChromosome analysis

  A digital chromosome-analysis system supporting chromosome counting, indexing, and karyotyping. It is designed for cytogenetic laboratories that need software-assisted organization and interpretation of chromosome images.

• ASI HiFISHFISH diagnostics

  A computational FISH platform for classification, scanning, imaging, and analysis. It is intended to support laboratory review of fluorescence signals and related diagnostic findings.

• ASI CytoPowerCytogenetics

  A cytogenetics platform combining chromosome analysis, karyotyping, and FISH cell classification. Its scope covers multiple steps in the digital cytogenetics workflow.

• ASI RainbowMulticolor microscopy

  A multicolor imaging and analysis solution for fluorescence and bright-field samples. It is intended for applications requiring the capture and interpretation of multiple optical channels.

• 2017Expansion into integrated digital pathologyProduct launch

  ASI's earlier cytogenetics and fluorescence expertise provided a base for entering broader pathology imaging and tissue-analysis workflows.

  What changed. The company introduced PathFusion and HiPath Pro for bright-field pathology, whole-slide imaging, IHC analysis, and tissue-related FISH workflows.

  Aftermath. ASI broadened its positioning from cytogenetics imaging to a wider digital pathology and laboratory imaging portfolio.

  Source
• 2011Launch of GenASIs and tray-loading automationProduct launch

  The company sought to digitize more of the diagnostic workflow and increase the number of samples that could be processed with less manual handling.

  What changed. ASI launched the GenASIs software platform and introduced a high-throughput tray loader for sample and scanning automation.

  Aftermath. The product portfolio expanded from imaging hardware toward integrated software, algorithmic analysis, and laboratory workflow management.

  Source
• 2005Move toward automated scanningStrategy

  Clinical laboratories were processing increasing sample volumes while facing shortages of laboratory personnel.

  What changed. ASI launched an automated scanning system intended to raise throughput and reduce repetitive manual image-acquisition work.

  Aftermath. The company's product direction increasingly emphasized faster turnaround, workflow automation, and computer-assisted laboratory analysis.

  Source
• 2002Expansion into clinical cytogeneticsStrategy

  ASI had initially focused on spectral-imaging devices for research users and identified clinical cytogenetics as a broader commercial application.

  What changed. The company introduced CytoLabView for karyotyping and FISH imaging.

  Aftermath. This established a clearer clinical direction for the company's imaging and analysis technologies.

  Source

1. Applied Spectral Imaging
2. Applied Spectral Imaging official website